Overview

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Status:
RECRUITING
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
United States Department of Defense
Treatments:
Psilocybin